- Home
- SENEB vs CMMB Comparison
SENEB vs CMMB Comparison
Compare SENEB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | CMMB |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | United States | Israel |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.5M | 13.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SENEB | CMMB |
|---|---|---|
| Price | $145.12 | $1.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 400.0 | ★ 72.7K |
| Earning Date | 02-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $12.93 | $43.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $86.92 | $0.87 |
| 52 Week High | $139.35 | $3.86 |
Technical Indicators
Market Signals| Indicator | SENEB | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 72.91 | 41.35 |
| Support Level | $108.68 | $1.48 |
| Resistance Level | N/A | $1.64 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | 1.69 | -0.04 |
| Stochastic Oscillator | 99.98 | 4.13 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.